| 13.09 0 (0%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 15.31 | 1-year : | 17.88 |
| Resists | First : | 13.1 | Second : | 15.31 |
| Pivot price | 13.03 |
|||
| Supports | First : | 13.01 | Second : | 12.96 |
| MAs | MA(5) : | 13.02 |
MA(20) : | 13.03 |
| MA(100) : | 11.91 |
MA(250) : | 9.21 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 65.4 |
D(3) : | 44.2 |
| RSI | RSI(14): 64.5 | |||
| 52-week | High : | 13.13 | Low : | 4.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FNA ] has closed below upper band by 13.5%. Bollinger Bands are 88.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.14 - 13.21 | 13.21 - 13.26 |
| Low: | 12.88 - 12.97 | 12.97 - 13.05 |
| Close: | 12.97 - 13.1 | 13.1 - 13.21 |
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Fri, 16 May 2025
Dimensional Fund Advisors LP Increases Position in Paragon 28, Inc. (NYSE:FNA) - Defense World
Thu, 15 May 2025
Barclays PLC Increases Position in VirTra, Inc. (NASDAQ:VTSI) - Defense World
Tue, 13 May 2025
Paragon 28 (FNA) Projected to Post Earnings on Wednesday - Defense World
Thu, 08 May 2025
Wells Fargo & Company MN Grows Position in Paragon 28, Inc. (NYSE:FNA) - Defense World
Tue, 06 May 2025
Barclays PLC Acquires 5,846 Shares of Paragon 28, Inc. (NYSE:FNA) - Defense World
Thu, 01 May 2025
Legal & General Group Plc Sells 1,319 Shares of Paragon 28, Inc. (NYSE:FNA) - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 84 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 31.2 (%) |
| Held by Institutions | 50.8 (%) |
| Shares Short | 1,070 (K) |
| Shares Short P.Month | 1,440 (K) |
| EPS | -0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.55 |
| Profit Margin | -21.4 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | -8.2 % |
| Return on Equity (ttm) | -36.4 % |
| Qtrly Rev. Growth | 18.5 % |
| Gross Profit (p.s.) | 2.28 |
| Sales Per Share | 3.05 |
| EBITDA (p.s.) | -0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -19.84 |
| PEG Ratio | 0 |
| Price to Book value | 8.39 |
| Price to Sales | 4.28 |
| Price to Cash Flow | -40.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|